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Abstract The system of membrane receptor Fas and its
ligand FasL compose one of the main pathways triggering
apoptosis. However, the role of their soluble forms has not
been clariﬁed yet. Although sFasL can be converted from
the membrane-bound form by matrix metalloproteinases
(MMPs), there are no data on relations between sFas/
sFasL, MMPs and their tissue inhibitors (TIMPs) in
patients on chronic dialysis—neither children nor adults.
The aim of our study was to evaluate serum concentrations
of sFas, sFasL, and their potential regulators (MMP-2,
MMP-7, MMP-9, TIMP-1, TIMP-2), in children and young
adults chronically dialyzed. Twenty-two children on auto-
mated peritoneal dialysis (APD), 19 patients on hemodi-
alysis (HD) and 30 controls were examined. Serum
concentrations of sFas, sFasL, MMPs and TIMPs were
assessed by ELISA. Median values of sFas, sFasL, sFas/
sFasL ratio, MMP-2, MMP-7, MMP-9, TIMP-1 and
TIMP-2 were signiﬁcantly elevated in all dialyzed patients
vs. controls, the highest values being observed in subjects
on HD. A single HD session caused the decrease in values
of all parameters to the levels below those seen in children
on APD. Regression analysis revealed that MMP-7 and
TIMP-1 were the best predictors of sFas and sFasL con-
centrations. Children and young adults on chronic dialysis
are prone to sFas/sFasL system dysfunction, more pro-
nounced in patients on hemodialysis. The correlations
between sFas/sFasL and examined enzymes suggest that
MMPs and TIMPs take part in the regulation of cell death
in the pediatric population on chronic dialysis, triggering
both anti- (sFas) and pro-apoptotic (sFasL) mechanisms.
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Introduction
Patients with chronic kidney disease (CKD) are prone to
enhanced apoptosis, additionally accelerated by the dialysis
procedure and the type of membrane that has been used [1,
2]. The system of membrane receptor Fas and its ligand
FasL compose one of the main pathways leading to pro-
grammed cell death. Fas, expressed on a wide variety of
cells, binds to its ligand, restricted mainly to macrophages,
T lymphocytes and endothelial cells, thus triggering the
apoptotic pathway [3].
Recent investigation has correlated these events with
vascular damage and subsequent progression of athero-
sclerosis, being another hallmark of CKD [4]. Indeed,
vascular smooth muscle cells (VSMCs) are resistant to
apoptosis in atherosclerotic lesions [5] and sensitive to it in
normal vessels [6]. Therefore, it has been suggested that
FasL-induced apoptosis in normal vessel wall acts in a
protective way by decreasing neointimal hyperplasia and
thickening [7], whereas in atherosclerosis this mechanism
seems ineffective, paradoxically increasing cell migration
and inﬂammation [5].
The soluble forms of death receptor and its ligand, sFas
and sFasL, have recently been discovered, but their role in
control of apoptosis has not been clariﬁed yet. sFasL is
proteolytically shed from its membrane-bound form by
enzymes—matrix metalloproteinases (MMPs) [8]. The
strongest evidence for such activity has been shown in
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The applicability of this regulatory pathway in clinical
practice has focused on overcoming drug resistance to
chemotherapy [10, 11] or controlling mesangial inﬂam-
mation [12], but it has not been considered in the light of
chronic kidney disease so far. The pro-apoptotic activity of
sFasL is decreased in comparison to that of the membrane
FasL [13]. Therefore, there is controversy whether such
conversion from the membrane-bound to the circulating
form may be regarded as an anti-apoptotic mechanism,
controlled by matrix metalloproteinases, or is it still the
pro-apoptotic feature in the sFasL characteristics that pre-
vails [14]. Despite evidence for pro-apoptotic and anti-
inﬂammatory activity of FasL, taking part in protection
against neointimal hyperplasia after vascular injury [7], the
parallel proﬁle has not been proven in the case of sFasL.
sFas acts in an anti-apoptotic way by blocking both FasL
and sFasL in a 1:1 proportion. It has also been deﬁned as a
marker of inﬂammation and endothelial dysfunction in
adults with coronary artery disease and chronic kidney
disease [15, 16]. Experimental data have shown the role of
sFas in protecting the vessel wall integrity against injury
[17]. However, the role of matrix metalloproteinases in
sFas shedding is unknown and there are no data on rela-
tions between sFas/sFasL, MMPs, their tissue inhibitors
(TIMPs) and inﬂammation/endothelial function in patients
with end stage renal disease. The investigation comparing
those parameters in the subjects treated with different
dialysis modalities is lacking either.
Therefore, our aim was to assess the serum levels of
sFas, sFasL and the values of sFas/sFasL ratio as a marker
of overall apoptotic activity, in children and young adults
on peritoneal dialysis and hemodialysis, searching for the
differences between those modalities. We also investigated
the correlations between sFas, sFasL, their potential regu-
lators—matrix metalloproteinases (MMP-2, MMP-7 and
MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2),
as well as clinical signiﬁcance of these ﬁndings, in the
pediatric population on dialysis.
Materials and methods
Seventy-one patients enrolled in the study were divided
into three groups. Data are shown in Table 1.
The ﬁrst group consisted of 22 children on automated
peritoneal dialysis (APD—Baxter, Home choice), 5 of
them having residual renal function. The patients had 5–8
exchanges during the night and, if necessary, one or two
during the day. Peritoneal ﬂuids used in our patients had
glucose concentrations varying from 1.36 to 2.27%. The
causative factors in CKD were: chronic pyelonephritis
(seven cases), chronic glomerulonephritis (six), polycystic
kidney disease (two), neurogenic bladder (three), hemo-
lytic uremic syndrome (two) and unknown (two).
The second group included nineteen children and young
adults hemodialyzed (HD) on polysulfone (PS) mem-
branes, only three out of them with residual kidney func-
tion. HD sessions (3.5–4 h) were performed three times a
week, using bicarbonate dialysate, the blood ﬂow ranged
from 150 to 200 ml/min, dialysate ﬂow did not exceed
500 ml/min. The membrane area was between 1.0 and
1.6 m
2, the dialyzers were not reused. The water, puriﬁed
by reosmosis, was regularly checked for contamination. All
patients were on stable anticoagulation regimen using low-
molecular-weight heparin. The causative factors in chronic
renal failure were: chronic glomerulonephritis (seven
cases), chronic pyelonephritis (seven), neurogenic bladder
(two), polycystic kidney disease (one) and unknown (two).
Thirty age-matched children with primary nocturnal
enuresis and normal kidney function, served as controls.
None of the patients showed clinical evidence of
infection, had diabetes, malignancies or vasculitides,
smoked, took antibiotics, statins, corticosteroids or immu-
nosuppressive therapy. All APD children had their blood
pressure values below the 90th percentile, adjusted for
gender and age, according to the criteria of the fourth
report on high blood pressure in children and adolescents
[18], and did not require anti-hypertensives. The blood
pressure in our HD patients was within normal values
without medication (12 patients) or was well controlled
with the use of ACE inhibitors only (3) or ACE inhibitors
with calcium channel blockers (4).
Informed consent was obtained from the subjects and
their parents, if necessary. The research project has been
approved by the University ethics committee, in accor-
dance with the Helsinki declaration.
Blood samples were drawn after an overnight fast from
peripheral veins in APD patients and controls, in HD
subjects—from the afferent line of the ﬁrst-use dialyzer
before starting an HD session. Samples were clotted for
30 min, centrifuged at 4C for 10 min, and then serum was
stored at -20C until assayed. Serum concentrations of
sFas, sFasL, MMP-2 (gelatinase A), MMP-7 (matrilysin),
MMP-9 (gelatinase B), TIMP-1 and TIMP-2 were evalu-
ated by commercially available ELISA kits (R&D Systems,
Abingdon, UK). Standards and serum samples were
transferred to 96 well microplates pre-coated with recom-
binant antibodies to human sFas, sFasL, MMP-2, MMP-7,
MMP-9, TIMP-1 and TIMP-2. Each sample was tested in
duplicate and the arithmetical mean was considered a ﬁnal
result. Measurements were performed according to the
manufacturer’s instructions, results were calculated by
reference to standard curves.
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inﬂammation (nephelometry by Dade Behring, Marburg,
Germany), was also evaluated.
Statistical analysis
Results are expressed as median values and interquartile
ranges. Differences between all groups and between the
values before and after a single dialysis session were
evaluated by using nonparametric tests (Kruskall–Wallis,
Mann–Whitney U, Wilcoxon). The relations between
parameters were assessed by Spearman’s correlation
coefﬁcient and by linear regression analysis. The linear
regression equations were calculated as y = bx ? a( yi s
the dependent variable, b is the regression coefﬁcient, x is
the independent variable, a is the constant term). We pre-
sented only those equations where both regression coefﬁ-
cient and constant term were statistically signiﬁcant.
Statistical analysis was performed using the package Stat-
istica ver. 9.0. A p value\0.05 was considered signiﬁcant.
Results
sFas, sFasL
sFas and sFasL median values were signiﬁcantly higher in
all dialyzed patients when compared to controls (p\0.01)
and the levels in the HD subgroup were higher than in the
APD subjects (Figs. 1, 2). A single hemodialysis session
decreased the concentrations of both parameters to the
values below those seen in children on APD, yet they
remained increased vs. controls.
Table 1 The median values and interquartile ranges of basic demographical data and examined parameters in the patients on peritoneal dialysis
(APD), on hemodialysis (HD) and in the control group
Parameter Median values (interquartile ranges) of analyzed parameters
Control gr. (n = 30) HD (n = 19) APD (n = 22)
Age (years) 10.0 (5.5–15.5) 13.5 (10.5–17.0) 10.0 (4.0–15.5)
Gender 16 girls; 14 boys 10 girls; 9 boys 12 girls; 10 boys
Time of therapy – 2.2 year (1.0–2.7) 2.0 year (0.7–2.5)
Before HD After HD
hsCRP (mg/l) 0.62 (0.28–1.34) 0.77 (0.2–3.56) 0.91 (0.21–7.69) 0.59 (0.29–1.40)
MMP-2 (ng/ml) 109.93
# (90.47–116.98) 332.35 (324.52–349.49) 197.99 (195.47–202.09)* 291.03
## (279.28–298.55)
MMP-7 (ng/ml) 2.18
# (2.13–2.23) 4.73 (4.59–4.83) 3.83 (3.75–3.89)* 4.16
## (4.14–4.23)
MMP-9 (ng/ml) 97.2
# (91.8–100.8) 744.3 (722.8–756.3) 171.1 (164.8–174.3)* 624.6
## (594.4–650.0)
TIMP-1 (ng/ml) 82.3
# (80.4–85.1) 440.4 (423.6–469.4) 145.1 (136.6–146.5)* 159.2
## (152.0–163.3)
TIMP-2 (ng/ml) 41.88
# (39.5–43.45) 251.45 (249.3–253.05) 152.75 (147.35–157.55)* 171.95
## (155.5–176.2)
Mann–Whitney U test:
#p\0.0001 APD, HD vs. control group,
##p\0.001 APD vs. after HD
Wilcoxon test: *p\0.0001 after HD vs. before HD
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Fig. 1 Serum sFas concentrations in patients on HD before and after
a single session, in children on APD and in controls
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Fig. 2 Serum sFasL concentrations in patients on HD before and
after a single session, in children on APD and in controls
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123sFas/sFasL ratio
The values of the ratio were elevated in children on dialysis
in comparison to the control group, being the highest in the
hemodialyzed subjects (Fig. 3). The HD session dimin-
ished them, but without signiﬁcant difference between
post-hemodialysis and APD patients.
MMPs and TIMPs
The median values of MMP-2, MMP-7, MMP-9, TIMP-1
and TIMP-2 were increased in the population on dialysis
when compared to the controls and the highest values were
observed in patients on hemodialysis (Table 1). A single
HD session diminished their concentrations to the levels
lower than those observed in children on peritoneal dialysis
(Table 1).
hsCRP
High sensitivity CRP levels did not show signiﬁcant
differences between dialyzed children and controls
(Table 1), and a single HD session had no impact on its
concentration.
Linear regression analysis
In all dialyzed patients, sFas, sFasL, MMPs and TIMPs
correlated with each other (Table 2). Although all MMPs
and TIMPs predicted the values of sFas and sFasL
(Table 3), MMP-7 and TIMP-1 were the most accurate
ones.
No associations between sFas/sFasL and hsCRP were
observed.
Discussion
Our study describes for the ﬁrst time the disturbed sFas/
sFasL system, and the potential role of MMPs and TIMPs
in its regulation, in children with end stage renal failure on
dialysis.
sFas concentrations were increased in all patients on
dialysis, which is concordant with previous observations in
adults [17, 19, 20]. Such elevation may be a consequence
of molecule accumulation due to decreasing GFR [19].
Perianayagam et al. have noticed that sFas levels in dia-
lysed patients were higher than in pre-dialysis subjects,
which may point at the dialysis per se as a procedure
aggravating sFas release [19]. The accelerated synthesis of
sFas, as a protective anti-apoptotic mechanism, cannot be
neglected either [21]. sFas levels increase also with age
[22]. Indeed, when we compared the concentrations of sFas
in corresponding groups of children and adults [19], the
latter were much higher. Additionally, sFas is a marker of
atherosclerosis, endothelial dysfunction and coronary
artery calciﬁcation—features characteristic for uremia [16,
23, 24].
However, the results concerning differences in sFas
concentrations between various dialysis modalities are
inconsistent. The probable source of discrepancies might
be the difference between examined populations, con-
cerning number of subjects and their age. However, the
impact of methodology cannot be neglected either. Peri-
anayagam et al. [19] reported on sFas levels being higher in
patients on PD than in those on high-ﬂux hemodialysis,
whereas Dalboni et al. [17] found no difference between
adults on continuous ambulatory peritoneal dialysis
(CAPD) and subjects dialyzed on reused polysulfone
membranes. None of the above mentioned conditions were
similar to ours, because we examined children, performing
APD and low-ﬂux HD on ﬁrst-use dialysers.
This is also the ﬁrst report on the inﬂuence of a single
hemodialysis session on sFas concentrations. The post-
dialysis drop in sFas levels may be of various origins. As a
middle molecule (*50 kd), it can be only partly cleared
during hemodialysis procedure. However, the adsorption
on the membrane surface, as well as formation of sFas-
sFasL complexes, also have to be taken into account.
Although a single HD session was able to correct the sFas
discrepancies to the levels below those seen in APD, this
effect seems transient. It is probable, however, that the
enlargement of total hemodialysis dose, e.g. by increasing
its frequency, would ameliorate the patients’ status by
diminishing the overall apoptotic activity and avoiding
sinusoidal changes in sFas concentrations between sub-
sequent sessions. The high sFas levels in patients on
chronic dialysis may also picture an attempt to protect
vulnerable tissues against apoptosis, and in a long term
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Fig. 3 The values of sFas/sFasL ratio in patients on HD before and
after a single session, in children on APD and in controls
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123perspective—diminish the risk of vascular calciﬁcation
[25]. However, although promising, this theory needs to be
veriﬁed in the future investigation.
Studies evaluating sFasL in the population on chronic
dialysis are even less numerous that those concerning sFas.
Perianayagam et al. [19] observed no difference between
the concentrations of sFasL in healthy controls, pre-dialysis
subjects and those on dialysis, irrespective of the method
used. Kirmizis et al. [26] found no improvement in apop-
tosis markers after a 6-month course of hemodialysis on
vitamin E-coated membranes vs. other membranes used
earlier, but they did not compare those values with the
control group of healthy subjects. In our population, sFasL
behaved similarly to sFas—there was a signiﬁcant increase
in all dialyzed children, with preponderance in those on
hemodialysis. The sFasL elevation might result from the
combination of mFasL overexpression on inﬂammatory
cells, characteristic for increased apoptosis, and overac-
tivity of MMPs and TIMPs, additionally triggering the
sFasL shedding [27]. The accumulation due to renal failure
is also possible, although the inverse correlation, existing
between GFR and sFas, has not been conﬁrmed in the case
of sFasL. A single HD session diminished the sFasL con-
centrations to the values lower than those in APD patients.
That decrease, even more evident than in the case of sFas,
may be attributed to the fact that sFasL is a molecule
smaller that sFas (*30 vs. 50 kd) and its clearance is more
effective. The adsorption on the membrane surface and
formation of sFas-sFasL complexes, should also be taken
into account as alternative explanations. Last, but not least,
the long-term effect of the transient intradialytic leukope-
nia cannot be neglected either.
However, the unresolved problem is whether sFasL, due
to its decreased apoptotic potential vs. mFasL, should be
regarded as an anti- or pro-apoptotic factor. Indeed, when
the increased overall activity of mFasL on immunocom-
petent cells in uremia is considered, the weaker pro-
apoptotic impact of sFasL vs. mFasL cannot compensate
the overexpression of the latter and, therefore, cannot be
interpreted solely as an anti-apoptotic action. Likewise, the
Table 2 Correlations between examined parameters in all children on dialysis (APD ? HD)
Parameter MMP-2 MMP-7 MMP-9 TIMP-1 TIMP-2
sFas R = 0.23 R = 0.79 R = 0.68 R = 0.84 R = 0.69
p = 0.14 p = 0.0000001 p = 0.000002 p = 0.0000001 p = 0.000001
sFasL R = 0.38 R = 0.72 R = 0.62 R = 0.73 R = 0.79
p = 0.02 p = 0.0000001 p = 0.00003 p = 0.0000001 p = 0.0000001
sFas/sFasL ratio R =- 0.45 R =- 0.67 R =- 0.61 R =- 0.67 R =- 0.81
p = 0.004 p = 0.000003 p = 0.00004 p = 0.000003 p = 0.0000001
R Spearman’s rank coefﬁcient
Table 3 The linear regression analysis of assessed parameters in all children and young adults on dialysis (APD ? HD)
Dependent variable Independent variable Regression
coefﬁcient b
Constant
term
Coefﬁcient of
determination R
2
p
sFas (pg/ml) MMP-2 (ng/ml) 13.03 7155.71 0.14 0.02
MMP-7 (ng/ml) 4051.91 -6827.72 0.85 0.000001
MMP-9 (ng/ml) 11.87 2907.77 0.55 0.001
TIMP-1 (ng/ml) 8.31 8781.47 0.90 0.000001
TIMP-2 (ng/ml) 20.94 6799.97 0.66 0.00001
sFasL (pg/ml) 48.88 5762.81 0.85 0.000001
sFasL (pg/ml) MMP-2 (ng/ml) 0.27 26.73 0.17 0.01
MMP-7 (ng/ml) 77.53 -233.89 0.87 0.000001
MMP-9 (ng/ml) 0.23 -51.28 0.59 0.0002
TIMP-1 (ng/ml) 0.16 64.52 0.94 0.000001
TIMP-2 (ng/ml) 0.44 19.77 0.80 0.00003
sFas/sFasL ratio MMP-2 (ng/ml) -0.14 146.37 0.15 0.02
MMP-7 (ng/ml) -35.50 261.28 0.63 0.000001
MMP-9 (ng/ml) -0.11 177.47 0.42 0.00007
TIMP-1 (ng/ml) -0.07 124.82 0.69 0.000001
TIMP-2 (ng/ml) -0.22 149.07 0.70 0.000001
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123fact that sFas and sFasL antagonize each other by stoi-
chiometric binding 1:1, speaks in favor of their ambiguous
activities. Moreover, recent investigation in knockout mice
has suggested that high levels of sFasL may trigger auto-
immune reactions and promote tumorigenesis [28].
Therefore, the best way to assess the overall apoptotic
activity would rather be to evaluate the proportion between
the concentrations of sFas and sFasL. The values of sFas/
sFasL ratio followed the same pattern as both parameters
analyzed separately, with one exception. The difference
between post-hemodialysis and APD subjects has vanished,
suggesting that the overall apoptotic ability of patients on
peritoneal dialysis is comparable to that in patients after a
HD session. Consequently, subjects on hemodialysis are
prone to ﬂuctuations, whereas children on peritoneal dial-
ysis seem fairly stable, which is of paramount importance,
as this modality is a method of choice in pediatric popu-
lation with end stage renal disease.
The subject of sFas/sFasL relation to MMPs and TIMPs
has never been described in patients with chronic kidney
disease. We have previously reported on increased con-
centrations of MMP-7 and TIMP-1 in children on chronic
dialysis, with their values being higher in hemodialyzed
patients than in those on peritoneal dialysis [29]. Our
currently extended panel has also covered gelatinases
(MMP-2, MMP-9) and TIMP-2, showing the similar pat-
tern of discrepancy between children on APD and HD.
Like in the case of sFasL, all parameters decreased after a
HD session to the levels below those seen in APD children,
probably due to both adsorption on the dialysis membrane
and formation of MMP-TIMP complexes. This concor-
dance could also result from the potential regulatory role of
MMPs and TIMPs in shedding sFasL from its membrane-
bound form mFasL. Moreover, all MMPs and TIMPs could
predict sFasL concentrations in the dialyzed population.
Among these, MMP-7 and TIMP-1 turned out to be the
best predictors of sFaL. While MMP-7 occupies an estab-
lished position of an enzyme critical in sFasL formation
[10–12], the inﬂuence of TIMP-1 on the process is a new
ﬁnding. Nevertheless, the fact that TIMP-1 is a MMP-9
speciﬁc inhibitor, and the suppression of the latter pro-
motes apoptosis, could render a probable explanation for
the observed correlation [30]. The discrepancies in accu-
racy of prediction between various MMPs and TIMPs
may result from alternative cleavage sites, thus creating
forms with different activity and individual apoptotic
potential [9].
Another intriguing question is whether MMPs and
TIMPs can also take part in the regulation of sFas shed-
ding, thus inﬂuencing apoptosis, inﬂammation and endo-
thelial function. So far, the only known way of sFas
synthesis is that by the alternatively spliced mRNA, so the
role of MMPs and TIMPs in mFasL cleavage seems
questionable [31]. However, sFasL correlations with pro-
teases may merely suggest that those enzymes could be
considered markers of inﬂammation and endothelial dys-
function. Therefore, the real nature of relations between
sFas, MMPs and TIMPs requires further investigation.
Summary
Children and young adults on chronic dialysis present with
sFas/sFasL system dysfunction and increased apoptotic
activity, less pronounced in patients on peritoneal dialysis.
The correlations between sFas/sFasL, MMPs and TIMPs
suggest that those enzymes may inﬂuence the programmed
cell death by stimulating both protective (sFas) and
destructive (sFasL) mechanisms responsible for apoptosis
in that group of patients.
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